Credit Suisse Ag Bio Atla, Inc. Transaction History

Credit Suisse Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$2.13 - $5.38 $27,592 - $69,692	-12,954 Reduced 99.94%	8 $0
Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $4,336 - $18,592	990 Added 8.27%	12,962 $65,000
Q4 2021 Feb 14, 2022	SELL	$19.0 - $30.95 $19,950 - $32,497	-1,050 Reduced 8.06%	11,972 $235,000
Q3 2021 Nov 12, 2021	BUY	$29.44 - $43.74 $216,501 - $321,663	7,354 Added 129.75%	13,022 $384,000
Q2 2021 Aug 16, 2021	BUY	$38.07 - $56.17 $215,780 - $318,371	5,668 New	5,668 $240,000

23.4M

30.8K

57K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $14.9M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.